| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
KOR/κ opioid receptor
|
|---|---|
| References | |
| Additional Infomation |
Objective: This article provides a detailed review of the chemical and pharmacological properties of novel non-fentanyl synthetic opioid receptor agonists, particularly N-substituted benzamides and acetamides (commonly known as U-class drugs) and 4-aminocyclohexanols developed by Upjohn in the 1970s and 1980s. Methods: This article tracks the emergence of these drugs as substances of abuse using peer-reviewed literature, patents, professional literature, data from international early warning systems, and discussion posts on drug user forums. Results: In terms of impact on the drug market, prevalence, and harm, the most influential compound to date is U-47700 (trans-3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide), which users report producing transient euphoria and inducing relapse. Since U-47700 was internationally regulated in 2017, a series of structurally similar related compounds (derived from the original patented compound) have appeared on the illicit drug market. Interest appears to be increasing in a structurally unrelated opioid developed by Upjohn (now known as BDPC/bromadol), and should be closely monitored. Conclusion: International early warning systems are an important component of tracking emerging psychoactive substances and help in taking countermeasures and collecting relevant data for detailed risk assessment. It is recommended that preliminary studies be conducted on the most likely new compounds to provide drug metabolism and pharmacokinetic data to ensure early detection of new substances in toxicological samples. Since these compounds are chiral, stereochemistry has a significant impact on their potency, so configuration determination should be considered in the detection methods. [1]
|
| Molecular Formula |
C19H26N2OCL2.HCL
|
|---|---|
| Molecular Weight |
405.789
|
| Exact Mass |
404.118
|
| Elemental Analysis |
C, 56.24; H, 6.71; Cl, 26.21; N, 6.90; O, 3.94
|
| CAS # |
109620-49-7
|
| Related CAS # |
(-)-U-50488 hydrochloride;114528-79-9;(±)-U-50488 hydrochloride;67197-96-0;(±)-U-50488 hydrate hydrochloride;(+)-U-50488;67198-17-8;(+)-U-50488 hydrochloride;114528-81-3
|
| PubChem CID |
91826457
|
| Appearance |
White to light yellow solid powder
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
25
|
| Complexity |
428
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
Cl.ClC1=CC=C(CC(N(C2CCCC[C@H]2N2CCCC2)C)=O)C=C1Cl
|
| InChi Key |
KGMMGVIYOHGOKQ-MVFUPKDGSA-N
|
| InChi Code |
InChI=1S/C19H26Cl2N2O.ClH/c1-22(19(24)13-14-8-9-15(20)16(21)12-14)17-6-2-3-7-18(17)23-10-4-5-11-23;/h8-9,12,17-18H,2-7,10-11,13H2,1H3;1H/t17?,18-;/m1./s1
|
| Chemical Name |
2-(3,4-dichlorophenyl)-N-methyl-N-[(2R)-2-pyrrolidin-1-ylcyclohexyl]acetamide;hydrochloride
|
| Synonyms |
U 50488 hydrochloride; 109620-49-7; 2-(3,4-dichlorophenyl)-N-methyl-N-[(2R)-2-pyrrolidin-1-ylcyclohexyl]acetamide;hydrochloride; U-50488 hydrochloride; 2-(3,4-Dichloro-phenyl)-N-methyl-N-(trans-2-pyrrolidin-1-yl-cyclohexyl)-acetamide hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 125 mg/mL
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (Infinity mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (Infinity mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (Infinity mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4643 mL | 12.3216 mL | 24.6433 mL | |
| 5 mM | 0.4929 mL | 2.4643 mL | 4.9287 mL | |
| 10 mM | 0.2464 mL | 1.2322 mL | 2.4643 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
